In This Article:
-
Net Revenue (Q4 2024): $10.4 million, an 11.6% increase over the prior year period.
-
Net Revenue (Full Year 2024): $38 million.
-
Product Revenue (Q4 2024): Kristalose: $4.4 million, Sancuso: $2.4 million, Vibativ: $2.1 million, Caldolor: $1.4 million.
-
Product Revenue (Full Year 2024): Kristalose: $15.3 million, Sancuso: $9 million, Vibativ: $6.9 million, Caldolor: $5 million.
-
Total Operating Expenses (Q4 2024): $12.3 million, down from $15.5 million in the prior year period.
-
Total Operating Expenses (Full Year 2024): $44.3 million, a $5 million improvement from the prior year.
-
Net Loss (Q4 2024): Approximately $1.9 million.
-
Net Loss (Full Year 2024): $6.5 million.
-
Adjusted Loss (Full Year 2024): $1.5 million or $0.11 per share.
-
Total Assets (End of 2024): $76 million, including $18 million in cash and cash equivalents.
-
Total Liabilities (End of 2024): $53 million, including $15.3 million on the credit facility.
-
Total Shareholders' Equity (End of 2024): $23 million.
-
Tax Net Operating Loss Carry-forwards: $53 million.
Release Date: March 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) reported a significant 11.6% increase in net revenues for Q4 2024, reaching $10.4 million.
-
The company achieved FDA approval for its antibiotic Vibativ in China, expanding its international market presence.
-
CPIX's ifetroban product candidate showed positive Phase II study results for Duchenne muscular dystrophy, boosting investor confidence and share price.
-
The company successfully transferred manufacturing for Sancuso to a new facility, enhancing production capabilities.
-
CPIX continues to expand its product pipeline with promising developments in treating systemic sclerosis and idiopathic pulmonary fibrosis.
Negative Points
-
CPIX reported a net loss of $1.9 million for Q4 2024 and $6.5 million for the full year, indicating ongoing financial challenges.
-
Despite revenue growth, the company still faces high operating expenses, totaling $12.3 million for Q4 2024.
-
The company's financial performance is heavily reliant on a few key products, which could pose risks if market conditions change.
-
CPIX's share repurchase program indicates a focus on stock price support rather than reinvestment in business growth.
-
The company faces significant competition in the pharmaceutical industry, which could impact future revenue growth and market share.
Q & A Highlights
Q: Can you provide an update on the progress of your ifetroban product candidate? A: A.J. Kazimi, CEO, explained that ifetroban is being evaluated in Phase II clinical trials for several unmet medical needs. The product has been dosed in nearly 1,400 subjects and has shown to be safe and well-tolerated. A recent Phase II study in patients with Duchenne muscular dystrophy showed promising results, with significant improvements in heart function. The company plans to complete a full data analysis and meet with the FDA to discuss the next steps for development and commercialization.